title: Thrombophilic risk factors in patients with severe carotid atherosclerosis.
abstract: Carotid stenosis and atrial fibrillation are the strongest risk factors for ischemic stroke. Ongoing prevention efforts include the identification of novel factors that increase the risk for carotid atherosclerosis. The aim of this study was to determine the thrombophilic risk profile of patients with severe carotid stenosis by evaluating a number of genetic and metabolic risk factors [factor (F)II G20210A, factor V Leiden, MTHFR C677T polymorphisms, anticardiolipin antibodies (aCL), lipoprotein(a) (Lp(a)), and homocysteine (Hcy)]. The study population consisted of 615 patients [(410 M/205 F; median age 73 (26-94) years] with severe (> 70%) carotid stenosis, and 615 apparently healthy subjects [(410 M/205 F; age 73 (31-92) years]. On multivariate analysis, independent risk factors were elevated Hcy [odds ratio (OR) 7.6, 95% confidence interval (CI) 4.8, 11.8] and Lp(a) levels (OR 2.9, 95% CI 2.1, 3.9), the presence of aCL (OR 5.7, 95% CI 3.1, 10.4) and heterozygosity for FII G20210A polymorphism (OR 2.8, 95% CI 1.3, 5.9). In the subgroup of women, independent risk factors for severe carotid atherosclerosis were: high levels of Hcy and Lp(a) and the presence of aCL, whereas hyperhomocysteinemia, elevated Lp(a) levels, aCL, FII G20210A and MTHFR 677TT polymorphisms remained independent risk factors in the subgroup of men. The results of the present study demonstrate that the prevalence of the thrombophilic risk factors is increased in patients with severe carotid atherosclerosis.
authors.affiliation: Thrombosis Center, University of Florence, Dipartimento del Cuore e dei Vasi, Center for the Study at Molecular and Clinical Level of Chronic, Degenerative and Neoplastic Diseases to Develop Novel Therapies, Firenze, Italy. r.marcucci@dac.unifi.it
authors.forename: R
authors.initials: R
authors.lastname: Marcucci
authors.forename: F
authors.initials: F
authors.lastname: Sofi
authors.forename: S
authors.initials: S
authors.lastname: Fedi
authors.forename: B
authors.initials: B
authors.lastname: Lari
authors.forename: I
authors.initials: I
authors.lastname: Sestini
authors.forename: A P
authors.initials: AP
authors.lastname: Cellai
authors.forename: R
authors.initials: R
authors.lastname: Pulli
authors.forename: G
authors.initials: G
authors.lastname: Pratesi
authors.forename: C
authors.initials: C
authors.lastname: Pratesi
authors.forename: G F
authors.initials: GF
authors.lastname: Gensini
authors.forename: R
authors.initials: R
authors.lastname: Abbate
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017153:Antibodies, Anticardiolipin / Q000097:blood; D001161:Arteriosclerosis / Q000097:blood / Q000209:etiology / Q000235:genetics; D002340:Carotid Artery Diseases / Q000097:blood / Q000209:etiology / Q000235:genetics; D016893:Carotid Stenosis / Q000097:blood / Q000209:etiology* / Q000235:genetics; D016022:Case-Control Studies; D005165:Factor V; D005260:Female; D006801:Humans; D020138:Hyperhomocysteinemia / Q000150:complications; D016682:Lupus Coagulation Inhibitor / Q000097:blood; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics; D008875:Middle Aged; D015999:Multivariate Analysis; D011516:Prothrombin / Q000235:genetics; D012307:Risk Factors; D019851:Thrombophilia / Q000097:blood* / Q000150:complications / Q000235:genetics*
chemical_list: D017153:Antibodies, Anticardiolipin; D016682:Lupus Coagulation Inhibitor; C095381:factor V Leiden; D005165:Factor V; D011516:Prothrombin; D042965:Methylenetetrahydrofolate Reductase (NADPH2)